Source 1primary paper2026MED
Toolkit/chimeric antigen receptor macrophages
chimeric antigen receptor macrophages
Also known as: CAR-M, CAR-M therapy
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
Chimeric antigen receptor macrophages (CAR-M) therapy presents a promising new avenue for GBM treatment, leveraging its inherent tumor-homing capacity, TME reprogramming function, and potential to bridge innate and adaptive immunity.
Usefulness & Problems
Why this is useful
CAR-M therapy uses engineered macrophages as a GBM-directed cell therapy platform. The abstract attributes to it tumor homing, TME reprogramming, and the ability to connect innate and adaptive immune responses.; glioblastoma treatment strategies; tumor microenvironment reprogramming; bridging innate and adaptive immunity
Source:
CAR-M therapy uses engineered macrophages as a GBM-directed cell therapy platform. The abstract attributes to it tumor homing, TME reprogramming, and the ability to connect innate and adaptive immune responses.
Source:
glioblastoma treatment strategies
Source:
tumor microenvironment reprogramming
Source:
bridging innate and adaptive immunity
Problem solved
The platform is presented as a way to address major GBM barriers including the immunosuppressive TME, intratumoral heterogeneity, and blood-brain barrier-related treatment failure.; addresses barriers posed by immunosuppressive tumor microenvironment; addresses limited tumor access through macrophage tumor-homing capacity
Source:
The platform is presented as a way to address major GBM barriers including the immunosuppressive TME, intratumoral heterogeneity, and blood-brain barrier-related treatment failure.
Source:
addresses barriers posed by immunosuppressive tumor microenvironment
Source:
addresses limited tumor access through macrophage tumor-homing capacity
Problem links
addresses barriers posed by immunosuppressive tumor microenvironment
LiteratureThe platform is presented as a way to address major GBM barriers including the immunosuppressive TME, intratumoral heterogeneity, and blood-brain barrier-related treatment failure.
Source:
The platform is presented as a way to address major GBM barriers including the immunosuppressive TME, intratumoral heterogeneity, and blood-brain barrier-related treatment failure.
addresses limited tumor access through macrophage tumor-homing capacity
LiteratureThe platform is presented as a way to address major GBM barriers including the immunosuppressive TME, intratumoral heterogeneity, and blood-brain barrier-related treatment failure.
Source:
The platform is presented as a way to address major GBM barriers including the immunosuppressive TME, intratumoral heterogeneity, and blood-brain barrier-related treatment failure.
Published Workflows
Objective: Engineer a macrophage cell therapy that targets CD47+ cancer cells effectively in solid tumors while reducing erythrocyte toxicity through tumor-microenvironment-specific activation.
Why it works: The abstract states that intrinsic Arg1 promoter responsiveness enables TME-specific activation of cytotoxicity, which is presented as a way to preserve antitumor activity against CD47+ cancer cells while minimizing erythrocyte toxicity.
Arg1 promoter-responsive activation in the tumor microenvironmentovercoming SIRPα inhibition against CD47+ cancer cellsmacrophage engineeringchimeric antigen receptor cell therapy
Objective: Translate CAR-M therapy for glioblastoma from preclinical concept toward early-phase clinical testing while prioritizing mechanistic validation.
Why it works: The proposed pathway is expected to work by using biomarker-supported mechanistic validation in early-phase clinical trials to answer fundamental questions about CAR-M homing, survival, and function in patients before broader efficacy claims are made.
tumor homingtumor microenvironment reprogrammingbridging innate and adaptive immunitymechanistic validationcombinatorial approachessmart technologiesbiomarker analyses
Stages
- 1.Mechanistic validation in early-phase clinical trials(confirmatory_validation)
The stage exists because the review identifies a translational gap and states that clinical efficacy in GBM remains unproven, so mechanistic questions in patients should be prioritized.
Selection: Use biomarker-supported early-phase clinical testing to answer fundamental biological questions about CAR-M homing, survival, and function in patients.
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A composed arrangement of multiple parts that instantiates one or more mechanisms.
Mechanisms
bridging innate and adaptive immunityTranslation Controltumor homingtumor microenvironment reprogrammingTarget processes
selectiontranslationImplementation Constraints
cofactor dependency: cofactor requirement unknownencoding mode: genetically encodedimplementation constraint: context specific validationimplementation constraint: multi component delivery burdenoperating role: regulatorswitch architecture: multi component
The abstract indicates that CAR-M translation depends on target selection, engineering design, delivery strategy, and biomarker-supported mechanistic evaluation. It also discusses optimization approaches such as armoring modifications, logic-gated designs, and convection-enhanced delivery.; requires target selection strategies; requires engineering design optimization; may require delivery optimization such as convection-enhanced delivery; may require biomarker-supported mechanistic validation in early-phase trials
The abstract explicitly states that clinical efficacy in GBM remains unproven. It also notes unresolved issues including phenotypic inactivation, antigen escape, and uncertainty in extrapolating preclinical evidence to patients.; clinical efficacy in GBM remains unproven; subject to target selection and engineering bottlenecks; vulnerable to TME-driven phenotypic inactivation and antigen escape
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Observations
mixedHuman Clinicaltherapeutic usehuman
Inferred from claim c2 during normalization. Despite promising preclinical data, clinical efficacy of CAR-M therapy in glioblastoma remains unproven. Derived from claim c2. Quoted text: However, despite promising preclinical data, clinical efficacy in GBM remains unproven.
Source:
Supporting Sources
Ranked Claims
Despite promising preclinical data, clinical efficacy of CAR-M therapy in glioblastoma remains unproven.
However, despite promising preclinical data, clinical efficacy in GBM remains unproven.
The review identifies armoring modifications, logic-gated designs, and convection-enhanced delivery as optimization approaches for CAR-M translational bottlenecks in glioblastoma.
We then focus on bottlenecks such as target selection strategies, engineering design, and TME-driven issues like phenotypic inactivation and antigen escape, discussing corresponding optimization approaches like armoring modifications, logic-gated designs, and convection-enhanced delivery.
CAR-M therapy is presented as a promising therapeutic avenue for glioblastoma because of tumor-homing capacity, tumor microenvironment reprogramming, and the potential to bridge innate and adaptive immunity.
Chimeric antigen receptor macrophages (CAR-M) therapy presents a promising new avenue for GBM treatment, leveraging its inherent tumor-homing capacity, TME reprogramming function, and potential to bridge innate and adaptive immunity.
Approval Evidence
1 source3 linked approval claimsfirst-pass slug chimeric-antigen-receptor-macrophages
Chimeric antigen receptor macrophages (CAR-M) therapy presents a promising new avenue for GBM treatment, leveraging its inherent tumor-homing capacity, TME reprogramming function, and potential to bridge innate and adaptive immunity.
Source:
clinical statussupports
Despite promising preclinical data, clinical efficacy of CAR-M therapy in glioblastoma remains unproven.
However, despite promising preclinical data, clinical efficacy in GBM remains unproven.
Source:
optimization strategysupports
The review identifies armoring modifications, logic-gated designs, and convection-enhanced delivery as optimization approaches for CAR-M translational bottlenecks in glioblastoma.
We then focus on bottlenecks such as target selection strategies, engineering design, and TME-driven issues like phenotypic inactivation and antigen escape, discussing corresponding optimization approaches like armoring modifications, logic-gated designs, and convection-enhanced delivery.
Source:
therapeutic rationalesupports
CAR-M therapy is presented as a promising therapeutic avenue for glioblastoma because of tumor-homing capacity, tumor microenvironment reprogramming, and the potential to bridge innate and adaptive immunity.
Chimeric antigen receptor macrophages (CAR-M) therapy presents a promising new avenue for GBM treatment, leveraging its inherent tumor-homing capacity, TME reprogramming function, and potential to bridge innate and adaptive immunity.
Source:
Comparisons
Source-stated alternatives
The abstract does not name alternative effector-cell platforms as direct comparators, but it does mention combinatorial approaches and smart technologies as complementary translational strategies.
Source:
The abstract does not name alternative effector-cell platforms as direct comparators, but it does mention combinatorial approaches and smart technologies as complementary translational strategies.
Source-backed strengths
inherent tumor-homing capacity; tumor microenvironment reprogramming function; potential to bridge innate and adaptive immunity
Source:
inherent tumor-homing capacity
Source:
tumor microenvironment reprogramming function
Source:
potential to bridge innate and adaptive immunity
Compared with cLIPS2
chimeric antigen receptor macrophages and cLIPS2 address a similar problem space because they share selection, translation.
Shared frame: same top-level item type; shared target processes: selection, translation; shared mechanisms: translation_control
Strengths here: looks easier to implement in practice.
Compared with CRISPR/Cas9
chimeric antigen receptor macrophages and CRISPR/Cas9 address a similar problem space because they share selection, translation.
Shared frame: same top-level item type; shared target processes: selection, translation; shared mechanisms: translation_control
Strengths here: may avoid an exogenous cofactor requirement.
Relative tradeoffs: appears more independently replicated.
Compared with CRISPR/Cas9 system
chimeric antigen receptor macrophages and CRISPR/Cas9 system address a similar problem space because they share selection, translation.
Shared frame: same top-level item type; shared target processes: selection, translation; shared mechanisms: translation_control
Relative tradeoffs: appears more independently replicated; looks easier to implement in practice.
Ranked Citations
- 1.